A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）

NCT03137368 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

CYP2D6 Polymorphism

Interventions

DRUG: Exemestane Tablets
OTHER: ovarian function suppression/ablation
GENETIC: CYP2D6*10 gene test
DRUG: Tamoxifen

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators

[object Object]